Status:
UNKNOWN
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Adenoid Cystic Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
Adenoid cystic carcinoma (ACC) accounts for 24% of salivary gland malignant tumors, is characterized by frequent local recurrences and distant metastasis, mainly to lungs. Considering its origination ...
Detailed Description
Adenoid cystic carcinoma (ACC) is a rare tumor entity with a yearly incidence of 3-5 cases per million. ACC arises in the major salivary glands and more often in the minor salivary glands of the oroph...
Eligibility Criteria
Inclusion
- confirmed treated or untreated adenoid cystic carcinoma patients;
- 18F-FDG PET/CT within two weeks;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- known allergy against PSMA
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04801264
Start Date
September 1 2020
End Date
December 31 2022
Last Update
March 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730